KDR and glioma: Sunitinib was well tolerated in children and young adults with recurrent high- grade glioma or ependymoma. Sunitinib therapy significantly modulated plasma VEGFR2. Nevertheless, there were no sustained antitumor responses (Wetmore et al., 2016).